Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/226820
Seeking new polymorphs in pharmaceutical cocrystals: focus on furosemide–ethenzamide
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Polymorphism remains a critical challenge in the pharmaceutical industry due to its profound impact on the physicochemical and biopharmaceutical properties of active pharmaceutical ingredients (APIs). While pharmaceutical multicomponent materials (PMMs) such as cocrystals were initially believed to mitigate polymorphic risks through stabilization via non-covalent interactions, while modulating the properties of different APIs, recent studies have revealed a growing number of polymorphic PMMs, highlighting the need for targeted screening and structural understanding of these materials. In this work, we report the discovery and selective synthesis of a novel polymorph of the furosemide–ethenzamide (FUR–ETZ) cocrystal through kinetic crystallization via fast solvent evaporation. Solid-state characterization confirmed the formation of a polymorph with morphotropic packing relative to the known form, despite maintaining similar molecular conformation and hydrogen bonding motifs. Crystal structure analysis revealed that formII exhibits a lateral layer shift and increased surface polarity, resulting in enhanced aqueous solubility and a slightly higher melting point. In contrast, formI was shown to be thermodynamically more stable, both in dry and aqueous environments, as supported by lattice energy calculations and competitive slurry experiments. These findings underscore the relevance of polymorph screening in PMMs and demonstrate how subtle variations in crystal packing can critically influence the stability and performance of pharmaceutical cocrystals.
Subject (English)
Citation
Citation
MUÑOZ-HERNÁNDEZ, Estephany, et al. Seeking new polymorphs in pharmaceutical cocrystals: focus on furosemide–ethenzamide. Crystengcomm. 2026. Vol. 28, num. 88-100. ISSN 1466-8033. [consulted: 6 of June of 2026]. Available at: https://hdl.handle.net/2445/226820